IPATunity170
14 Dec 2020
IPATunity170
NCT04177108
A Phase III, Double-blind, Placebo-controlled, Randomized Study Of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer.
Hoffman-La Roche
Cancer Type | Breast |
---|---|
Trial Type | Treatment |
Phase | Phase III |
Age Range | 18 years and older |
Sex | Both |
Tumour Stream | - |
Cancer Stage | All stages |
Anticipated Start Date | 2019-11-19 |
Anticipated End Date | 2025-10-10 |
Hospital | Ashford Cancer Centre Research |
---|---|
Clinical Trial Coordinator | Sue Yeend |
syeend@adelaidecancercentre.com.au | |
Phone | 08 8292 2240 |
Principal Investigator | Dr Meen Okera |
Recruitment Status | Recruiting |